Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the American Association for Cancer Research (AACR) Annual Meeting 2022
04/01/2022 - 08:00 AM
NEWARK, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a poster presentation and two trials in progress at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from April 8-13, 2022.
Poster Presentation Title: Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors Abstract Number: 1174 / 4 Presenter: Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA Poster Session Date and Time: Monday, April 11, 2022, 9:00 a.m. – 12:30 p.m. CT Location: Poster Section 27 Trial in Progress Title: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53 -wild type and MDM2 -amplified advanced or metastatic solid tumors (MANTRA-2) Abstract Number: CT123/5 Presenter: Ecaterina I. Dumbrava, M.D., Medical Oncologist, The University of Texas MD Anderson Cancer Center Session Date and Time Monday, April 11, 2022, 9:00 a.m. – 12:30 p.m. CT Location: Poster Section 34 Trial in Progress Title: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas Abstract Number: CT235/6 Presenter: Mrinal M. Gounder, M.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center Session Date and Time: Tuesday, April 12, 2022, 1:30 p.m. – 5:00 p.m. CT Location: Poster Section 36
A copy of the presentation materials can be accessed by visiting the "Resources ” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.
About Rain Therapeutics Inc.
Media Contact jtemperato@lifescicomms.com
Investor Contact bob@lifesciadvisors.com
RAIN Rankings
#5336 Ranked by Stock Gains
RAIN Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
About RAIN
rain therapeutics is a san francisco bay area-based biotechnology company, focused on developing small molecule targeted therapeutics for cancer patients that possess a clear, and single, oncogenic driver.
